These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

110 related articles for article (PubMed ID: 15255315)

  • 1. [Managing Graves' orbitopathy].
    Kahaly GJ
    Z Arztl Fortbild Qualitatssich; 2004 May; 98 Suppl 5():63-6. PubMed ID: 15255315
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Endocrine orbitopathy 1998].
    Förster G; Kahaly G
    Med Klin (Munich); 1998 Jun; 93(6):365-73. PubMed ID: 9662944
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Optimal management of Graves orbitopathy: a multidisciplinary approach.
    Soeters MR; van Zeijl CJ; Boelen A; Kloos R; Saeed P; Vriesendorp TM; Mourits MP
    Neth J Med; 2011; 69(7):302-8. PubMed ID: 21934174
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Graves' orbitopathy].
    Balázs C
    Orv Hetil; 2006 Jun; 147(22):1011-7. PubMed ID: 16913090
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Thyroid dysfunction: managing the ocular complications of Graves' disease.
    Fries PD
    Geriatrics; 1992 Feb; 47(2):58-60, 63-4, 70. PubMed ID: 1735520
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Interdisciplinary diagnosis and treatment of endocrine orbitopathy (Graves' disease) (author's transl)].
    Wulle KG; Brunk G; Utech C; Pfannenstiel P
    Klin Monbl Augenheilkd; 1980 Nov; 177(5):551-5. PubMed ID: 6894774
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Management of Graves' orbitopathy: evidence-based recommendations].
    Ponto KA; Pitz S; Mann WJ; Weber MM; Pfeiffer N; Kahaly GJ
    Dtsch Med Wochenschr; 2009 Dec; 134(49):2521-4. PubMed ID: 19941237
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Etiology and treatment of Graves' disease (some problems)].
    Werner SC
    Nord Med; 1968 Dec; 80(49):1645-50. PubMed ID: 4191771
    [No Abstract]   [Full Text] [Related]  

  • 9. Multi-center study on the characteristics and treatment strategies of patients with Graves' orbitopathy: the first European Group on Graves' Orbitopathy experience.
    Prummel MF; Bakker A; Wiersinga WM; Baldeschi L; Mourits MP; Kendall-Taylor P; Perros P; Neoh C; Dickinson AJ; Lazarus JH; Lane CM; Heufelder AE; Kahaly GJ; Pitz S; Orgiazzi J; Hullo A; Pinchera A; Marcocci C; Sartini MS; Rocchi R; Nardi M; Krassas GE; Halkias A
    Eur J Endocrinol; 2003 May; 148(5):491-5. PubMed ID: 12720530
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Endocrinological findings in endocrine orbitopathy].
    Hädecke J; Schneyer U
    Klin Monbl Augenheilkd; 2005 Jan; 222(1):15-8. PubMed ID: 15678394
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Histomorphometric study of lymphocyte population in thyroid in Graves' disease after treatment (author's transl)].
    Franc B; Barres D; Baglin C; Garnier H; Mignot M; Mignot J
    Ann Pathol; 1981; 1(1):90-4. PubMed ID: 7018512
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Management of the active severe eye changes of Graves' disease.
    Werner SC
    Trans Am Acad Ophthalmol Otolaryngol; 1967; 71(4):631-7. PubMed ID: 6072401
    [No Abstract]   [Full Text] [Related]  

  • 13. Treatment of Graves' orbitopathy and its results. A retrospective analysis.
    Kahaly G; Böckmann H; Beyer J; Cordes U
    Dev Ophthalmol; 1989; 20():109-26. PubMed ID: 2687047
    [No Abstract]   [Full Text] [Related]  

  • 14. Thyroid eye disease.
    Mizen TR
    Semin Ophthalmol; 2003 Dec; 18(4):243-7. PubMed ID: 15513011
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Plasma exchange therapy for severe Graves' ophthalmopathy.
    Glinoer D; Schrooyen M; Winand R
    Dev Ophthalmol; 1989; 20():91-3. PubMed ID: 2591631
    [No Abstract]   [Full Text] [Related]  

  • 16. Perspectives in pharmacological management of Graves' hyperthyroidism and orbitopathy.
    Bartalena L; Lai A; Tanda ML
    Expert Rev Clin Immunol; 2008 May; 4(3):321-9. PubMed ID: 20476922
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Viral conjunctivitis interfering with the clinical activity score and management of thyroid ophthalmopathy.
    Boboridis KG; Konstas AG; Krassas GE; Georgiadis NS
    Orbit; 2006 Mar; 25(1):27-9. PubMed ID: 16527772
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Serum levels of the interferon-gamma-inducible alpha chemokine CXCL10 in patients with active Graves' disease, and modulation by methimazole therapy and thyroidectomy.
    Antonelli A; Fallahi P; Rotondi M; Ferrari SM; Serio M; Miccoli P
    Br J Surg; 2006 Oct; 93(10):1226-31. PubMed ID: 16838393
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A predictive mathematical model for the calculation of the final mass of Graves' disease thyroids treated with 131I.
    Traino AC; Di Martino F; Grosso M; Monzani F; Dardano A; Caraccio N; Mariani G; Lazzeri M
    Phys Med Biol; 2005 May; 50(9):2181-91. PubMed ID: 15843745
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A treatment strategy for Graves' orbitopathy.
    Marcocci C; Pinchera A; Marinò M
    Nat Clin Pract Endocrinol Metab; 2007 May; 3(5):430-6. PubMed ID: 17452970
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.